Chapter

General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma

Volume 2 of the series Methods of Cancer Diagnosis, Therapy, and Prognosis pp 441-464

Prostate Cancer: Detection and Monitoring Using Mitochondrial Mutations as a Biomarker

  • Gabriel D. DakuboAffiliated withGenesis Genomics, Inc. Email author 
  • , Ryan L. ParrAffiliated withGenesis Genomics, Inc.
  • , John P. JakupciakAffiliated withBiochemical Science Division, National Institute of Standards and Technology

* Final gross prices may vary according to local VAT.

Get Access

Neoplastic transformation of the prostate gland is one of the leading causes of cancer morbidity and mortality among men in the industrialized world. As an ageassociated disease, the incidence of prostate cancer (PCa) will remain on the rise, mirroring the ageing Western population. Similar to other cancers, PCa is debilitating when diagnosed late. Surgical resection of organ-confined tumors is the best available curative method. Therefore, to obtain optimal cure, it is imperative that methods are developed that enable early detection and monitoring of this disease. Epigenetic nuclear gene silencing and alterations in both nuclear and mitochondrial genomes precede histopathologic changes indicative of PCa. Thus, sensitive assays that target the genetic signatures should help with early detection and successful treatment of PCa.